
Although US lawmakers took one step closer to securing more affordable insulin for people with diabetes in the US, it’ll be of little consequence for the companies supplying the drugs, including Novo Nordisk, Eli Lilly and Sanofi, assesses Senior Equity Analyst at Sydbank Søren Løntoft Hansen.
On Thursday last week, the US House of Representatives passed a bill that if made law will cap patients’ expenses for a month’s supply of insulin at USD 35.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app